Skip to main content

Advertisement

SpringerLink
Log in

Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease

  • Original Article
  • Published:
Journal of Molecular Medicine Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Pompe disease is characterized by accumulation of both lysosomal and cytoplasmic glycogen primarily in skeletal and cardiac muscles. Mannose-6-phosphate receptor-mediated enzyme replacement therapy (ERT) with recombinant human acid α-glucosidase (rhGAA) targets the enzyme to lysosomes and thus is unable to digest cytoplasmic glycogen. Studies have shown that anti-DNA antibody 3E10 penetrates living cells and delivers “cargo” proteins to the cytosol or nucleus via equilibrative nucleoside transporter ENT2. We speculate that 3E10-mediated ERT with GAA will target both lysosomal and cytoplasmic glycogen in Pompe disease. A fusion protein (FabGAA) containing a humanized Fab fragment derived from the murine 3E10 antibody and the 110 kDa human GAA precursor was constructed and produced in CHO cells. Immunostaining with an anti-Fab antibody revealed that the Fab signals did not co-localize with the lysosomal marker LAMP2 in cultured L6 myoblasts or Pompe patient fibroblasts after incubation with FabGAA. Western blot with an anti-GAA antibody showed presence of the 150 kDa full-length FabGAA in the cell lysates, in addition to the 95- and 76 kDa processed forms of GAA that were also seen in the rhGAA-treated cells. Blocking of mannose-6-phosphate receptor with mannose-6-phosphate markedly reduced the 95- and the 76 kDa forms but not the 150 kDa form. In GAA-KO mice, FabGAA achieved similar treatment efficacy as rhGAA at an equal molar dose in reducing tissue glycogen contents. Our data suggest that FabGAA retains the ability of rhGAA to treat lysosomal glycogen accumulation and has the beneficial potential over rhGAA to reduce cytoplasmic glycogen storage in Pompe disease.

Key messages

  • FabGAA can be delivered to both the cytoplasm and lysosomes in cultured cells.

  • FabGAA equally reduced lysosomal glycogen accumulation as rhGAA in GAA-KO mice.

  • FabGAA has the beneficial potential over rhGAA to clear cytoplasmic glycogen.

  • This study suggests a novel antibody-enzyme fusion protein therapy for Pompe disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. van der Ploeg AT, Reuser AJ (2008) Pompe’s disease. Lancet 372(9646):1342–1353

    Article  PubMed  Google Scholar 

  2. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D (2006) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148(5):671–676

    Article  PubMed  Google Scholar 

  3. Muller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin Y, Pongratz D, Walter MC, Baethmann M, Schlotter-Weigel B, Lochmuller H et al (2007) Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 17(9–10):698–706

    Article  PubMed  Google Scholar 

  4. Kishnani PS, Beckemeyer AA, Mendelsohn NJ (2012) The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management. Am J Med Genet C Semin Med Genet 160(1):1–7

    Article  Google Scholar 

  5. Angelini C, Semplicini C (2012) Enzyme replacement therapy for Pompe disease. Curr Neurol Neurosci Rep 12(1):70–75

    Article  CAS  PubMed  Google Scholar 

  6. Case LE, Beckemeyer AA, Kishnani PS (2012) Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations. Am J Med Genet C Semin Med Genet 160(1):69–79

    Article  CAS  Google Scholar 

  7. Van Hove JL, Yang HW, Wu JY, Brady RO, Chen YT (1996) High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease. Proc Natl Acad Sci U S A 93(1):65–70

    Article  PubMed  PubMed Central  Google Scholar 

  8. Garancis JC (1968) Type II glycogenosis. Biochemical and electron microscopic study. Am J Med 44(2):289–300

    Article  CAS  PubMed  Google Scholar 

  9. Thurberg BL, Lynch Maloney C, Vaccaro C, Afonso K, Tsai AC, Bossen E, Kishnani PS, O’Callaghan M (2006) Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 86(12):1208–1220

    Article  CAS  PubMed  Google Scholar 

  10. Lewandowska E, Wierzba-Bobrowicz T, Rola R, Modzelewska J, Stepien T, Lugowska A, Pasennik E, Ryglewicz D (2008) Pathology of skeletal muscle cells in adult-onset glycogenosis type II (Pompe disease): ultrastructural study. Folia Neuropathol 46(2):123–133

    PubMed  Google Scholar 

  11. Griffin JL (1984) Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture. Virchows Arch B Cell Pathol Incl Mol Pathol 45(1):23–36

    Article  CAS  PubMed  Google Scholar 

  12. Rehman K, Hamid Akash MS, Akhtar B, Tariq M, Mahmood A, Ibrahim M (2016) Delivery of therapeutic proteins: challenges and strategies. Curr Drug Targets 17(10):1172–1188

    Article  CAS  PubMed  Google Scholar 

  13. Komin A, Russell LM, Hristova KA, Searson PC (2016) Peptide-based strategies for enhanced cell uptake, transcellular transport, and circulation: mechanisms and challenges. Adv Drug Deliv Rev. doi:10.1016/j.addr.2016.06.002

    PubMed  Google Scholar 

  14. Zack DJ, Stempniak M, Wong AL, Taylor C, Weisbart RH (1996) Mechanisms of cellular penetration and nuclear localization of an anti-double strand DNA autoantibody. J Immunol 157(5):2082–2088

    CAS  PubMed  Google Scholar 

  15. Hansen JE, Sohn W, Kim C, Chang SS, Huang NC, Santos DG, Chan G, Weisbart RH, Nishimura RN (2006) Antibody-mediated Hsp70 protein therapy. Brain Res 1088(1):187–196

    Article  CAS  PubMed  Google Scholar 

  16. Weisbart RH, Stempniak M, Harris S, Zack DJ, Ferreri K (1998) An autoantibody is modified for use as a delivery system to target the cell nucleus: therapeutic implications. J Autoimmun 11(5):539–546

    Article  CAS  PubMed  Google Scholar 

  17. Lawlor MW, Armstrong D, Viola MG, Widrick JJ, Meng H, Grange RW, Childers MK, Hsu CP, O’Callaghan M, Pierson CR et al (2013) Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy. Hum Mol Genet 22(8):1525–1538

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hansen JE, Tse CM, Chan G, Heinze ER, Nishimura RN, Weisbart RH (2007) Intranuclear protein transduction through a nucleoside salvage pathway. J Biol Chem 282(29):20790–20793

    Article  CAS  PubMed  Google Scholar 

  19. Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR (2001) Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun 280(3):951–959

    Article  CAS  PubMed  Google Scholar 

  20. Lu H, Chen C, Klaassen C (2004) Tissue distribution of concentrative and equilibrative nucleoside transporters in male and female rats and mice. Drug Metab Dispos 32(12):1455–1461

    Article  CAS  PubMed  Google Scholar 

  21. Raben N, Nagaraju K, Lee E, Kessler P, Byrne B, Lee L, LaMarca M, King C, Ward J, Sauer B et al (1998) Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 273(30):19086–19092

    Article  CAS  PubMed  Google Scholar 

  22. Maga JA, Zhou J, Kambampati R, Peng S, Wang X, Bohnsack RN, Thomm A, Golata S, Tom P, Dahms NM et al (2013) Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in Pompe mice. J Biol Chem 288(3):1428–1438

    Article  CAS  PubMed  Google Scholar 

  23. Joseph A, Munroe K, Housman M, Garman R, Richards S (2008) Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin Exp Immunol 152(1):138–146

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Hallgren P, Hansson G, Henriksson KG, Hager A, Lundblad A, Svensson S (1974) Increased excretion of a glucose-containing tetrasaccharide in the urine of a patient with glycogen storage disease type II (Pompe’s disease). Eur J Clin Invest 4(6):429–433

    Article  CAS  PubMed  Google Scholar 

  25. Yi H, Thurberg BL, Curtis S, Austin S, Fyfe J, Koeberl DD, Kishnani PS, Sun B (2012) Characterization of a canine model of glycogen storage disease type IIIa. Dis Model Mech 5(6):804–811

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Amalfitano A, McVie-Wylie AJ, Hu H, Dawson TL, Raben N, Plotz P, Chen YT (1999) Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc Natl Acad Sci U S A 96(16):8861–8866

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Young SP, Stevens RD, An Y, Chen YT, Millington DS (2003) Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry. Anal Biochem 316(2):175–180

    Article  CAS  PubMed  Google Scholar 

  28. Yi H, Fredrickson KB, Das S, Kishnani PS, Sun B (2013) Stbd1 is highly elevated in skeletal muscle of Pompe disease mice but suppression of its expression does not affect lysosomal glycogen accumulation. Mol Genet Metab 109(3):312–314

    Article  CAS  PubMed  Google Scholar 

  29. Moreland RJ, Jin X, Zhang XK, Decker RW, Albee KL, Lee KL, Cauthron RD, Brewer K, Edmunds T, Canfield WM (2005) Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor. J Biol Chem 280(8):6780–6791

    Article  CAS  PubMed  Google Scholar 

  30. Raben N, Danon M, Gilbert AL, Dwivedi S, Collins B, Thurberg BL, Mattaliano RJ, Nagaraju K, Plotz PH (2003) Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 80(1–2):159–169

    Article  CAS  PubMed  Google Scholar 

  31. Raben N, Jatkar T, Lee A, Lu N, Dwivedi S, Nagaraju K, Plotz PH (2002) Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. Mol Ther 6(5):601–608

    Article  CAS  PubMed  Google Scholar 

  32. Sun B, Zhang H, Bird A, Li S, Young SP, Koeberl DD (2009) Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression. J Gene Med 11(10):913–920

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Stewart KM, Horton KL, Kelley SO (2008) Cell-penetrating peptides as delivery vehicles for biology and medicine. Org Biomol Chem 6(13):2242–2255

    Article  CAS  PubMed  Google Scholar 

  34. Skotland T, Iversen TG, Torgersen ML, Sandvig K (2015) Cell-penetrating peptides: possibilities and challenges for drug delivery in vitro and in vivo. Molecules 20(7):13313–13323

    Article  CAS  PubMed  Google Scholar 

  35. Sarko D, Beijer B, Garcia Boy R, Nothelfer EM, Leotta K, Eisenhut M, Altmann A, Haberkorn U, Mier W (2010) The pharmacokinetics of cell-penetrating peptides. Mol Pharm 7(6):2224–2231

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by a grant from Valerion Therapeutics (Concord, MA). We thank Dr. Tracy R. McKnight for reviewing and editing the manuscript. We also thank Ms. Fengqin Gao for her assistance with animal care.

Author information

Author notes

    Authors and Affiliations

    1. Division of Medical Genetics, Department of Pediatrics, Duke University School of Medicine, Durham, NC, 27710, USA

      Haiqing Yi, Tao Sun, Chunyu Yang, Stephanie Austin, Priya S. Kishnani & Baodong Sun

    2. Valerion Therapeutics, Concord, MA, 01742, USA

      Dustin Armstrong

    3. Borneman Consulting, Del Mar, CA, 92014, USA

      Scott Borneman

    Authors
    1. Haiqing Yi
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Tao Sun
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Dustin Armstrong
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Scott Borneman
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Chunyu Yang
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Stephanie Austin
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Priya S. Kishnani
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Baodong Sun
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Baodong Sun.

    Ethics declarations

    Conflict of interest

    D. Armstrong is the founder of Valerion Therapeutics and declares ownership interest in the company. All other authors declare no competing or financial interests.

    Additional information

    Haiqing Yi and Tao Sun contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Yi, H., Sun, T., Armstrong, D. et al. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease. J Mol Med 95, 513–521 (2017). https://doi.org/10.1007/s00109-017-1505-9

    Download citation

    • Received:

    • Revised:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00109-017-1505-9

    Keywords

    Search

    Navigation